Exposure Assessment for Sterilized Medical Devices: Implications for Microbiological Risk Analysis

1990 ◽  
pp. 119-128
Author(s):  
Herbert C. Hammond ◽  
William C. Dierksheide
Author(s):  
Karolina Jagiello ◽  
Anita Sosnowska ◽  
Alicja Mikolajczyk ◽  
Tomasz Puzyn

This article gives a brief description of the existing regulations related to biomaterials safety that need to be considered before it is introduced into EU market. According to these regulations, the risk analysis should include two characteristics: probability of occurrence of harm, and severity. Identified user-related harm should be reduced by managing the risk. Additionally, the review presents an overview of engineered biomaterials (EBMs), which in combination with nanoscale components (NPs) have shown promises in Advanced Therapy Medicinal Products (ATMP) and Medical Devices (MD). In this article, recent challenges, objectives and perspectives in risk assessment and risk management of ATMP and MD composed of nanobiomaterials were also highlighted.


Author(s):  
J. Christopher Bouwmeester ◽  
Vicki Komisar ◽  
Arushri Swarup

Abstract – A simulation is used to facilitate cooperative and team-based learning to introduce concepts of human factors, risk analysis, and quality control applied to the design of medical devices. We further use a friendly game-based approach to simulate the dynamics between a customer, a regulatory agency, and competitive manufacturers. Students are divided into manufacturing teams/companies and teaching assistants act as the customer and regulator. To promote positive interdependence and individual accountability, each student within a company is assigned roles of CEO, inspector, marketer, and designer. The goal for each company is to design and produce as many eye patch medical devices as possible, which must be approved by the regulator, within a tight deadline. Products are evaluated by the customer, who decides what price to pay for each unit, at the end of production. The most successful company is determined by the greatest amount of money earned after two rounds of production and sales.


Work ◽  
2012 ◽  
Vol 41 ◽  
pp. 5860-5865 ◽  
Author(s):  
Long Liu ◽  
Ma Shuai ◽  
Zhu Wang ◽  
Ping Li

1988 ◽  
Vol 7 (4) ◽  
pp. 509-518
Author(s):  
Joseph V. Rodricks ◽  
Stephen L. Brown

The tools of risk assessment are now applied in the regulation of most classes of commercially produced chemicals, and there appear to be good reasons to apply the technique to potentially hazardous chemical constituents of medical devices. If it is to be applied, several sets of issues and data requirements almost unique to device constituents risk assessment need to be explored. Most important of these are the issues of inter-route extrapolation and assessment of human exposure to device constituents. An example of the latter problem, involving residues of the device sterilant ethylene oxide, is provided to reveal the types of data needed to assess human exposure to device constituents. It also reveals the type of device usage database that has been developed to assist exposure assessment. Several suggestions for dealing with data gaps in all types of device risk assessment are provided.


Sign in / Sign up

Export Citation Format

Share Document